Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of zimberelimab and domvanalimab plus platinum-doublet chemotherapy versus pembrolizumab plus platinum-doublet chemotherapy as first-line treatment for metastatic non-small cell lung cancer
MOH_2023-01-11_012278Phase 3Recruiting
- Sponsor
- Gilead Sciences
- Start
- Nov 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of zimberelimab, domvanalimab and pembrolizumab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Gilead Sciences. Started Nov 2022; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2023-01-11_012278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-01-11_012278.